Introduction {#S1}
============

The idea that tumor initiation, progression and regrowth after treatment are sustained by a subpopulation of cancer cells, the glioblastoma stem cells (GSCs), has been crucial to our current understating of glioblastoma (GBM) biology ([@B59]; [@B2]; [@B5]; [@B19]; [@B35]). Glioblastoma is a highly aggressive brain tumor characterized by elevated intratumor heterogeneity, which could be potentially attributed to variations in GSC behavior and stochastic consequences of their hierarchical growth pattern. Recent studies provided evidence for a proliferative hierarchy in GBM, by using a combination of experimental approaches, such as quantitative lineage tracing, clonal size dependences, mutational signature analysis, and single cell RNA sequencing ([@B43]; [@B60]; [@B27]; [@B38]). Not only do these works indicated that tumor expansion follows a hierarchical lineage progression, but they also demonstrated that tumor cell fate decisions are rooted in a developmental program of neurogenesis. As such, early tumorigenesis is not primarily driven by genetic evolution, although genetic variations could still modulate the patterns self-renewal and differentiation of tumor cells, especially during later stages of disease progression. Evidence in another brain tumor originating in the cerebellum also showed that targeting the stem cell at the apex of a conserved developmental hierarchy could block tumor regrowth ([@B65]). Thus, the cancer stem cell (CSC) model applied to GBM provided a framework to understand tumor heterogeneity, predict tumor evolution, and might contribute to the identification of novel therapeutic targets aimed at eliminating the GSC in order to eradicate the tumor.

The simultaneous presence of different stem, progenitor, and differentiated cells along the developmental hierarchy and the high degree of intra-tumor heterogeneity render *in vitro* modeling of GBM particularly challenging. GSCs have been isolated from primary tumor biopsies and have been show to recapitulate *in vivo* tumor heterogeneity when forced to differentiate in culture or upon xenotransplantation ([@B17]; [@B57]; [@B46]; [Figure 1](#F1){ref-type="fig"}). However, when GSCs are grown in adherent 2D monolayer cultures, they lack intrinsic heterogeneity and 3D relative spatial organization, and lose interactions with the diverse components of the tumor extracellular matrix and the microenvironment. Moreover, these cells scarcely predict treatment efficacy, as drugs that initially proved effective in the context of cultured cell lines did not result in clinical applications ([@B72]).

![Timeline of *in vitro* method to culture neural stem cells and glioblastoma cells in 2D and 3D. Schematic representation of the development of different protocols to culture NSCs (neural stem cells) and GBM (glioblastoma) cells in monolayer, spheres and organoids. SFM, serum free medium; EGF, epidermal growth factor; FGF2, fibroblast growth factor 2; GFs, growth factors; NeoCOR, neoplastic cerebral organoids; GLICO, GLIoma cerebral organoids.](fcell-08-00220-g001){#F1}

Thus, more refined model systems that allow the recapitulation of complex cancer phenotypes and yet retain the amenability to perform detailed analysis are needed, especially in view of the need to provide more accurate predictions of the therapeutic potential of new treatments. Encouraged by promising results in other cancer fields ([@B9]; [@B63]; [@B55]; [@B62]), several laboratories have directed their efforts to generate organoid models of glioblastoma, which consist, by definition, of 3D structures in which different cell types self-organize to establish appropriate cell--cell contacts and to create a microenvironment ([@B22]). As such, GBM organoids could better mimic tumor complexity and heterogeneity in growth potential and treatment responsiveness. This review describes the existing organoid GBM models that have just started to be developed and compares them to other 3D models, such as neurospheres and 3D bioprinted GBMs. It also discusses their potential to advance our understanding of GBM biology and to predict clinical outcome, while also considering their current limitations.

Three-Dimensional Models of Glioblastoma {#S2}
========================================

Tumorspheres and Glioblastoma Organoids From Primary Tissue {#S2.SS1}
-----------------------------------------------------------

Glioblastoma stem cells can be isolated from primary tumors and can be grown in culture for an extended period of time ([@B23]; [@B20]; [@B17]; [@B57]; [@B61]; [@B71]; [@B15]; [@B46]; [@B67]; [Figure 1](#F1){ref-type="fig"} and [Table 1](#T1){ref-type="table"}). *In vitro* expansion of GSC is sustained by growth factors like EGF (Epidermal Growth Factor) and FGF2 (Fibroblast Growth Factor), conditions that also expand neural stem cells, highlighting the close relationship between GSC and their normal counterpart ([@B11]; [@B45], [@B46]). GSC can be grown in 2D adherent culture or as 3D neurospheres: the latter can be considered the very first "3D model" of GBM, as cells maintain a certain degree of polarization and 3D spatial organization ([@B17]; [@B4]). However, neurospheres are characterized by a necrotic core and can thus be able to achieve a maximum size of around 300 μm, before needing disruption and replating to survive ([@B53]; [@B58]; [@B52]). In addition, cells in neurospheres have lost their interaction with components of the extracellular matrix, and thus hardly mimic *in vivo* GSC behavior ([Table1](#T1){ref-type="table"}).

###### 

Overview of the characteristics of the different methods.

                                                        **2D**           **Spheres**                      **Organoids**                                                    
  ----------------------------------------------------- ---------------- -------------------------------- --------------- ------------- ---------------------------------- -----------------------------
  **Efficiency of derivation**                          100%             \<50%                            91.4%           n.d.          Oncogene-dependent                 100%
                                                                                                                                                                           
  **Time of culture establishment**                     1--2 weeks       1--2 weeks                       1--2 weeks      1--2 months   1--4 months                        1--2 months
                                                                                                                                                                           
  **Homogeneity (bulk analysis)**                       \+               ±                                --              --            --                                 --
                                                                                                                                                                           
  **Heterogeneity (maintenance of tumor complexity)**   --               --                               \+              \+            \+                                 \+
                                                                                                                                                                           
  **Relative 3D spatial distribution**                  --               --                               \+              \+            \+                                 \+
                                                                                                                                                                           
  **Genetic stability overtime**                        ±^a^             ±                                \+^b^           n.d^c^        n.a.^d^                            \+
                                                                                                                                                                           
  **Freeze/thaw**                                       \+               \+                               \+              --            --                                 --
                                                                                                                                                                           
  **Maximum time in culture**                           \>1 year         6--9 months                      \>1 month       \>1 year      1--2 months post electroporation   14--24 days post co-culture
                                                                                                                                                                           
  **Potential to predict response to treatment**        --               --                               \+              n.d.          \+                                 \+
                                                                                                                                                                           
  **GBM/non-GBM cell mix to study invasion**            --               --                               --              --            \+                                 \+
                                                                                                                                                                           
  **References**                                        [@B15]; [@B46]   [@B17]; [@B61]; [@B46]; [@B67]   [@B24]          [@B21]        [@B8]; [@B39]                      [@B39]; [@B33]

a

Genomic stability is maintained within the first 6 months of culture (

Pollard et al., 2009

); some features are rapidly lost, such as EGFR amplification (

Fael Al-Mayhani et al., 2009

;

Linkous et al., 2019

).

b

Genomic stability is maintained, but the analysis has been done at only 2 weeks in culture (

Jacob et al., 2020

).

c

n.d. not determined.

d

n.a., not applicable. GBO, GBM organoid; NeoCOR, neoplastic cerebral organoids; GLICO, GLIoma cerebral organoids.

In 2016, the lab of Jeremy Rich developed *in vitro* conditions to grow 3D organoids from human GBM cells and from GBM biopsies. When embedded in matrigel, finely minced GBM specimens grew up to 3--4 mm in 2 months and could be kept in culture for over a year ([Table 1](#T1){ref-type="table"}), even if their growth slows down after several months, probably due to the limited diffusion of nutrients as the organoids grow in size ([@B21]; [Figure 2A](#F2){ref-type="fig"}). An interesting feature of these GBM organoids is that they recapitulate the gradient of stem cell density in relation to hypoxic levels found *in vivo*. The authors reported a high number of Sox2+ stem cells at the periphery of the organoid, while the core was characterized by lower abundance of Sox2+ cells and increased levels of hypoxia. Sox2+ stem cells also exhibited different molecular properties when located at the core or at the periphery of the organoids ([@B21]). Thus, multiple Sox2+ populations may co-exist in organoids, suggesting that the organoid microenvironment might be able to sustain the simultaneous growth of different CSCs and would allow the study of cellular hierarchies in tumors. While highly promising, this system would require further characterization and validation across several GBMs. Indeed, establishment rates have yet to be determined and may be very patient-specific. Moreover, this system suffers from a relatively low to medium throughput capability and the long time necessary to establish the cultures (1--2 months) ([Table 1](#T1){ref-type="table"}).

![Three dimensional models of glioblastoma. **(A)** Glioblastoma (GBM) organoids have been derived by embedding finely minced GBM specimen in matrigel ([@B21]) or **(B)** by culturing pieces of tumor biopsies in defined matrigel-free and serum-free conditions, on an orbital shaker. GBO. GBM Organoid ([@B24]). **(C)** Embryonic stem (ES) cell-derived brain organoids can be nucleofected at early stages of the differentiation to introduce tumor-promoting genetic alterations. During nucleofection, cells are also marked with green fluorescent protein (GFP) to visualize tumor cell growth. NeoCOR, neoplastic cerebral organoids ([@B8]; [@B39]). **(D)** Patient-derived glioblastoma stem cells (GSCs) are initially cultured in 2D, before being co-cultured with brain organoids. GSCs are marked by GFP to visualize integration and growth in the organoid. GLICO, GLIoma cerebral organoids ([@B39]; [@B33]). **(E)** Patient-derived GBM cells and endothelial cells are seeded on a chip using a pig extracellular matrix (ECM) bio-ink and a 3D bioprinter ([@B70]).](fcell-08-00220-g002){#F2}

Recently, a novel and faster protocol (1--2 weeks) of 3D GBM organoid derivation that overcome such limitations has been reported by collaboration between Donald O'Rourke, Guo-li Ming, and Hongjun Song at the University of Pennsylvania ([Table 1](#T1){ref-type="table"} and [Figure 1](#F1){ref-type="fig"}). Instead of dissociating tumor biopsies to fine pieces, the authors cut the biopsies into around 1 mm fragments and culture them on an orbital shaker without matrigel and in serum free conditions not supplemented with EGF and FGF2 ([Figure 2B](#F2){ref-type="fig"}; [@B24]). These conditions should avoid selection of specific cell populations, thus better preserving inter- and intra-tumoral heterogeneity. These glioblastoma organoids, called GBOs, also developed hypoxic gradient and were further propagated in culture by cutting them into smaller pieces to avoid inner core necrosis. Importantly, these GBOs were cryopreserved and able to recover and continue their growth upon thawing. This is an essential step to generate GBM biobanks for subsequent recovery and analysis and the authors have currently biobanked around 70 GBOs from 53 patients (sometimes including different tumor subregions). GBOs largely maintain genetic and molecular signatures of the parental tumors. However, most analyses have been done within the first two weeks in culture, as GBOs maintenance over very long periods has been variable.

This novel protocol is fast and reproducible and provides enough material for RNA and exome sequencing, as well as drug sensitivity tests. It is thus suitable for genotype-drug association studies and opens new avenues to personalized medicine approaches, along the line of current advances in other cancer fields in which organoid biobanks have already been established or are currently being generated ([@B9]; [@B63]; [@B55]; [@B69]; [@B26]).

The establishment of the cultures within 1--2 weeks from surgical resection is particularly important, because current treatments are initiated within a month post-surgery and having preclinical information about potentially effective treatments might be extremely useful and might also help refine patient enrolment in clinical trials. In this direction, GBO treatment with CAR-T cells against EGFRvIII variant, which is currently in clinical trials ([@B41]; [@B18]), resulted in specific effect only on GBOs containing high percentage of EGFRvIII+ cells, thus showing the translational impact and future pre-clinical potential of this approach ([@B24]).

Tumor Development by Genetic Engineering of Brain Organoids {#S2.SS2}
-----------------------------------------------------------

The development of human brain organoids or "minibrians" have revolutionized the way we operate in developmental neurobiology, by providing unprecedented access to aspects of human brain development functioning and disorders ([@B25]; [@B31], [@B29]; [@B42]; [@B48], [@B47], [@B49]; [@B3]; [Figure 1](#F1){ref-type="fig"}). The potential of brain organoids to recapitulate aspects of brain cancer is particularly valuable as neither patient derived xenotransplantation in mice nor human brain tumor stem cells in 2D culture behave in the same way as tumors *in vivo*.

The labs of Jürgen Knoblich and Inder Verma have recently genetically engineered organoids to develop tumors ([@B8]; [@B39]; [Figures 1](#F1){ref-type="fig"}, [2C](#F2){ref-type="fig"} and [Table 1](#T1){ref-type="table"}). [@B8] screened for genetic alterations that could lead to tumorigenesis and called the resulting tumor NeoCor (neoplastic cerebral organoids): the authors overexpressed known oncogenes by a transposase-based system and/or deleted tumor suppressor gene functions via CRIPSR Cas-9. Organoid cells have been targeted by nucleofection at very early stages of the differentiation and the cells carrying the genetic alterations have been marked by GFP, so that cell growth and tumor transformation could be easily followed. This screening identified MYC overexpression and a few more genetic combinations often found in human GBM to provide cells with a strong growth advantage. Transcriptomic profiling showed that MYC overexpressing tumors have a CNS-PNET-like identity (CNS-PNET: Primitive Neuro-Ectodermal Tumor of the Central Nervous System), while the other tumors resemble GBM more, suggesting that distinct genetic aberrations can induce tumors with specific cellular identities. Other works have also shown that mesenchymal GBM can be induced in organoids by defined genetic mutations, namely HRasG12V activation and p53 disruption ([@B39]).

Although these works show that a certain degree of GBM subtyping can be reproduced in organoids, whether all different GBM subtypes can be recapitulated in this system and how closely GBM-derived organoids resemble patient-derived GBM cells is still under investigated. Tumors other than GBM did not develop despite the genetic manipulation of genes classically altered in these tumors, such as the deletion of the inhibitory Sonic Hedgehog (SHH) receptor PTCH1 in SHH-group medulloblastoma ([@B8]). However, the oncogenic effect of PTCH1 deletion is known to be cell-type specific ([@B56]) and might therefore necessitate organoid pre-differentiation down the cerebellar route for transformation to occur ([@B6]).

Co-culture of GBM Cells With Brain Organoids {#S2.SS3}
--------------------------------------------

Tumor models created by genetic engineering of organoids described above are particularly advantageous to effectively model GBM initiation, but they hardly recapitulate the genomic complexity of *in vivo* tumors, as the methodology requires genetic manipulation of the few known driver genes, which are not necessarily representative of the genomic GBM heterogeneity. The laboratory of Howard Fine and other laboratories have recently developed a novel approach that overcome this disadvantage, by co-culturing patient-derived GSCs with 3D brain organoids and called their model GLICO (GLIoma cerebral organoids; [@B33]; [Figures 1](#F1){ref-type="fig"}, [2D](#F2){ref-type="fig"} and [Table 1](#T1){ref-type="table"}). The authors co-cultured different GFP-marked GSC cell lines with fully grown cerebral brain organoids and demonstrated that GSCs proliferate over time and integrate into the organoids. Each line behaves in a unique way, with some lines showing diffuse invasion, others forming "honeycomb"-like structures and others forming small regional nodes of proliferation ([@B33]). Interestingly, co-cultured GSCs that exhibit higher degree of invasiveness were also more lethal when transplanted in mice ([@B39]). Thus, the observed heterogeneity in growth and invasion in the GLICO model likely reflects certain intrinsic properties of that particular patient-derived GSC line.

Cancer cells in this system not only displayed a cellular behavior that closely mimics the original tumor, but they also maintained key genetic aberrations of the native tumor. EGFR amplification, which was identified in two of the analyzed cell lines, was maintained in the GLICO models, while often lost in 2D cultures ([@B33]; [Table 1](#T1){ref-type="table"}), indicating that this model may provide a more suitable microenvironment to preserve the genetic background of the *in vivo* tumor.

Three-Dimensional GBM Model via Bioprinting {#S2.SS4}
-------------------------------------------

The use of advanced 3D bioprinting technologies could enhance the way we design 3D GBM models *in vitro* ([@B64]; [@B70]). [@B70] created a GBM-on-chip model, in which they used decellularized pig brain extracellular matrix as a bio-ink to seed patient-derived cancer cells together with vascular endothelial cells in separated compartments ([Figure 2E](#F2){ref-type="fig"}). Compartmentalization by seeding endothelial cells on the outside and cancer cells in the core of the chip established a radial oxygen gradient, which recapitulated important pathological features of the tumor. This model indeed exhibited hypoxia induced necrotic core, a perivascular niche and maintained a degree of spatial heterogeneity of the different cell types, with the higher number of Sox2+ stem cells at the periphery of the seeded tumor.

The "biomimetic" conditions of this system provided a microenvironment comparable to that of the original *in vivo* tumor tissue, offering the advantage of promoting cell-cell and cell-matrix interactions, and of better predicting treatment responses in a shorter time frame than other models (1--2 weeks compared to 1--2 months). However, the system still lacks accurate 3D spatial organization that can be only generated using self-assembled 3D organoid cultures, and it requires advanced technologies and expertise not always available to common biological laboratories.

Advantages and Limitations: Which Model to Use? {#S3}
===============================================

The best GBM model would be one that is complex enough to recapitulate features of the original tumor and simple enough to support investigation of different aspects of carcinogenesis in isolation. While the focus of this review is to look at emerging 3D *in vitro* models of GBM, several other approaches, including engineered mouse models or xenotransplantation, have been particularly useful to address tumor biology in other contexts \[for a review of GBM models *in vivo* and *in vitro*, see [@B54]\]. Thus, researchers might have to balance pros and cons of the different models to find the best fit for their research question, and might have to combine more than one model to take advantage of their complementary strengths ([Table 1](#T1){ref-type="table"}).

The development of 3D *in vitro* models of GBM holds great potential to study GBM biology and predict response to treatment, as they more closely recapitulate the complexity and heterogeneity of the original tumor. Indeed, most of the 3D organoid models described here have also shown selective vulnerabilities for targeted therapies or radiation that closely resemble tumor sensitivity *in vivo* ([@B21]; [@B8]; [@B33]). In addition, the recent establishment of 3D GBM organoids from biopsies with a novel and faster protocol (1--2 weeks) promoted the generation of a live GBM biobank that can be used for genotype-drug association studies on a medium to high throughput capability ([@B24]). Thus, 3D GBM models provide a powerful predicting tool that could be used one day to guide clinical decisions.

Some of the models described in this review ([@B8]; [@B39]; [@B33]) and other similar models ([@B12]; [@B44]) allow the possibility to mix GBM and non-GBM brain cells ([Table 1](#T1){ref-type="table"}). This is particularly useful to study tumor invasion of the normal tissue and the interaction of tumor cells with normal brain cells. By targeting only one or the other compartment at a time, it will thus be possible to dissect the specific role of genes involved in cell-cell interaction, adhesion, guidance and migration, and this might identify novel therapeutical targets to block tumor infiltration.

The brain organoid tissue GBM cells interact with, however, resembles more an embryonic type of tissue, rather than the adult brain tissue of GBM derivation. At present, it is not clear how this might influence tumor properties. In the future, it would be interesting to develop a similar approach to model and study prenatal and childhood tumors, such as pediatric gliomas and medulloblastomas, which should maintain a closer link to their developmental origin ([@B34]; [@B5]; [@B35]). As medulloblastoma did not develop in organoids, even when genetic alterations typical of this tumors were introduced, it might be necessary to generate regionalized organoids ([@B37]; [@B14]; [@B51]; [@B6]) tailored to the area of origin of that specific tumor, prior to transformation.

An aspect that has likely benefited from having this embryonic type of tissue, is the maintenance of the CSC compartment of the tumor. By providing cancer cells with the more appropriate environment that could support the simultaneous presence of different stem and progenitor cells, these 3D GBM organoid models will foster the investigation of CSC heterogeneity ([@B7]). They will also open the possibility to study CSC developmental hierarchy in tumors and the influence of other cell types or of the environment on CSC fate decisions. While it is possible to incorporate non-neuronal cell types into organoids, such as microglia or other immune cells ([@B1]; [@B10]; [@B40]; [@B24]), the main challenge still remains to recreate an environment that includes the vasculature and other cell types that could exhibit inflammatory and immunitary responses similar to an intact brain ([@B13]; [@B28]; [@B36]).

The presence of different cell types and the high degree of heterogeneity is probably the main advantage and, at the same time, a disadvantage of the system because, while it reflects the complexity of the original tumor, it is probably the source of variability typical of these 3D cultures ([@B30]; [@B50]; [@B3]; [@B49]; [@B66]; [Table 1](#T1){ref-type="table"}). Thus, investigators might have to choose between growing cells in classical 2D monolayer or sphere cultures or in 3D organoids depending on whether they are more interested in performing bulk analysis on an homogenous cell population or whether they aim to investigate tumor aspects that requires maintenance of tumor complexity and heterogeneity.

Conclusion and Perspectives {#S4}
===========================

The emerging development of 3D organoids of GBM adds on to an abundance of choices to model this aggressive brain tumor ([@B54]; [Figure 1](#F1){ref-type="fig"} and [Table 1](#T1){ref-type="table"}). It provides researchers with an additional tool to understand GBM biology, and predict tumor progression and response to treatment. One of the main advantages of growing GBM in brain organoids is the possibility to simultaneously grow different stem cells, progenitors and their differentiated progeny within the same conditions ([@B21]; [@B24]). This not only mimics better the heterogeneity of the original tumor, but it also shows the persistence of developmental programs of neurogenesis in the tumor. By understanding how CSCs make fate decisions and by defining the aberrant developmental pathways that lead to tumorigenesis, it will be possible to exploit novel emerging vulnerabilities to kill or differentiate CSCs to eradicate the tumor.

Future challenges include the reduction of organoid variability, while maintaining tumor complexity and heterogeneity, and the incorporation of an appropriate microenvironment that could, for example, mimic inflammatory and immunological responses. This would be particularly relevant in view of current successes in cancer immunotherapy ([@B16]) and, once incorporated in organoids, it would help to understand how immunological response might influence CSC hierarchy, and tumor progression and regrowth ([@B68]; [@B32]).

Our knowledge on GBM has massively expanded in the past decades and future collaborations between oncologists, clinicians, and researchers in the cancer, stem cell, and developmental biology fields, together with the possibility to share different complementary models and tools are likely to bring the long-sought breakthroughs that will improve patient treatment and prognosis.
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